Long-Term Safety of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C)

Summary

The main purpose of this study is to evaluate the long-term safety and tolerability of renzapride at a dose of 4 mg taken once daily for 12 months in women with constipation-predominant irritable bowel syndrome (IBS-C).

Timeline

Start

2006-04

Primary completion

2008-06

Completion

2008-06

Outcome

Outcome not reported

Stopped: “Terminated due to insufficient efficacy over placebo in Study ATL1251/038/CL.”

Drugs

Indications